
Mind Medicine Inc (NASDAQ:MNMD) is trading higher Tuesday morning after the company announced the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, allowing its Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder to proceed.
The previously announced clinical hold on the IND was lifted following MindMed’s responses for additional information related to the participant monitoring protocol in the upcoming study. Participant enrollment for the study is expected to start in early 2022.